Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

vibegron

PharmaDeviceNews vibegron

Representative image of a urologist discussing overactive bladder and benign prostatic hyperplasia treatment data with an older male patient, reflecting Sumitomo Pharma America’s AUA 2026 vibegron findings in men aged 75 and older.

Pharma & Biotech

Can vibegron strengthen Sumitomo Pharma America’s urology position after AUA 2026?

by Pallavi Madhiraju
May 18, 2026
0 Comments

Older men with OAB and BPH remain hard to treat. Sumitomo Pharma America’s vibegron data may sharpen the next urology market test.

Read More

Latest news and features

Forlong Biotechnology doses first patient in Australian Phase 1 trial of subcutaneous FL115
Natera’s Signatera Genome separates bladder cancer patients into 91%, 81% and 55% survival groups, but can MRD guide treatment?
Neurogene reports rapid MECP2 expression and new gene regulation data for NGN-401 in Rett syndrome
Dyno Therapeutics reports 152-fold brain transduction improvement and new immune-evasive AAV capsid data at ESGCT 2026
Rumi Therapeutics signs option agreement for IND-ready RTX-7340 PDE2 inhibitor in Fragile X syndrome
Powerful Medical secures CPT code 1139T for Queen of Hearts AI ECG after FDA authorisation
Kivo Health raises $10m Series A led by Allumia Ventures to expand AI-powered care for chronic lung disease
Alterome Therapeutics schedules first Phase 1 clinical data presentation for pan-KRAS inhibitor ALTA3263
Arrowhead Pharmaceuticals secures NHS funding recommendation for REDEMPLO in familial chylomicronaemia syndrome
Afimetoran Phase 2 trial delivers significant lupus improvement as Beeline Medicines eyes pivotal studies
Tafenoquine combinations show promising parasite clearance in immunocompromised patients with babesiosis
REYOBIQ brain cancer trial: Cerenome advances targeted radiotherapy ahead of Phase 2 plans

POPULAR NEWS

plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.

Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

August 19, 2026

Pharma & Biotech

Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?

October 27, 2026

Medical Devices & Diagnostics

Presage Technologies SmartSpectra cleared for contactless vital signs monitoring

July 8, 2026

Latest business and industry news

GE Vernova’s $9bn Trench deal follows $29bn orders as power backlog reaches $197bn
Enphase (NASDAQ: ENPH) has $1.08bn in solar agreements. Why the 16% fall?
EnerSys bets $320m on Ultralife’s military batteries and drone power systems as defence demand grows
Alphabet (NASDAQ: GOOGL) crashes after hours despite 103% Google Cloud growth as AI spending overwhelms cash flow
Magellan Aerospace joins Saab’s Gripen Canada plan, but how much fighter jet manufacturing work could it secure?

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.